InVivo Therapeutics Holdings Corp (NVIVQ)

[JKM1]

I certainly hope so. I'm just suggesting that it is extremely risky to complete the Inspire Study and then submit both the Inspire Study results and the Cohort Study results and gamble that the FDA buys into this as a substitute for a control arm. Certainly they have a strong indication or possible approval. If not it could set them back by several quarters, meanwhile depleting their cash.